Implantable cardiac defibrillator leads dysfunction after LVAD implantation.

Vincent GalandChristophe LeclercqHamed BourenaneStéphane BouléAndré VincentelliPhilippe MauryPierre MondolyFrançois PicardNicolas WeltéMichel KindoThomas CardiJean-Luc PasquiéPhilippe GaudardJean-Baptiste GourraudVincent ProbstPascal DefayeAude BoignardMarylou ParaVincent AlgalarrondoEdeline PelcéVlad GariboldiMatteo PozziJean-François ObadiaFrédéric AnselmePierre-Yves LitzlerKatrien BlanchartGerard BabatasiFabien GarnierMarie BielefeldDavid HamonNicolas LelloucheThierry BourguignonBertrand PierreRomain EschalierNicolas D'OstrevyEmilie VarletEloi MarijonHugues BlangyNicolas SadoulErwan FlécherRaphaël P Martins

Published in: Pacing and clinical electrophysiology : PACE (2020)

More than 50% of LVAD-recipients may experience >1 significant change in lead parameters but none had severe clinical consequences.

Keyphrases

left ventricular assist device
left ventricular
early onset
oxidative stress
cardiac resynchronization therapy
heart failure
kidney transplantation